These two GLUT1 inhibitors were able to inhibit cell proliferation and induce apoptosis in several breast cancer cell lines (MCF-7, MDA-MB-231, HBL100, and BT549), and these effects were accompanied by interference with cellular glucose handling, increasing the levels of extracellular glucose, and decreasing the levels of extracellular lactate, suggesting an inhibitory effect upon glucose uptake and/or glycolysis. Here, SLC2A1 is linked to breast carcinoma.